#USA #Chronic Pain #Aliso Viejo #Neuros Medical #Altius

Neuros Medical Secures $56 Million in Series D Funding

Neuros Medical, Inc. has made significant strides towards aiding those suffering from chronic pain due to amputation. The company has successfully completed a $56 million Series D funding round, paving the way for the commercialization of its Altius® Direct Electrical Nerve Stimulation System, which is an FDA-approved non-opioid solution for managing post-amputation pain.

The Altius® System: A Breakthrough in Pain Management

The Altius® system represents a revolutionary approach to treating chronic pain that commonly afflicts amputees. This groundbreaking system utilizes a unique technology to directly target pain signals transmitted from damaged peripheral nerves. By inhibiting these signals, Altius® offers a targeted and effective pain management solution.

Key Features of the Altius® System:

• - Patient-Controlled: Users can initiate a treatment session on demand, providing flexibility and control over their pain management.
• - On-Demand Relief: The system allows patients to request a 30-minute treatment session as needed, focusing precisely on their pain points.
• - FDA Approval: As the only FDA-approved device for this specific purpose, Altius® provides a significant clinical advantage.

The Journey to Funding

The Series D financing was led by EQT Life Sciences with participation from notable investors such as US Venture Partners and Amzak Health among others. In a statement, David Veino, President and CEO of Neuros Medical, expressed immense gratitude to both new and existing investors for their backing. He emphasized the importance of the Altius® system in addressing the pressing medical needs of the amputee community and highlighted the company’s mission to not only relieve pain but also restore quality of life for these individuals.

Unmet Medical Need Among Amputees

The numbers speak volumes; roughly 2 million people in the U.S. are living with limb loss, with 300,000 new amputations occurring annually. Studies have shown that up to 80% of amputees experience chronic pain, which can severely compromise their quality of life. Unfortunately, existing treatments primarily rely on opioids and other medications that can often lead to dependency and other adverse effects.

Neuros Medical is poised to change that narrative with the Altius® system. This innovative technology is designed to combat both phantom limb pain and residual limb pain — conditions that are often inadequately addressed by current medical practices. By offering a non-opioid solution, Neuros Medical is filling a critical gap in chronic pain management and paving the way for healthier outcomes.

Future Plans

With the new funding, Neuros Medical aims to facilitate the Altius® system's entry into the U.S. market while continuing its ongoing research and development. The goal is not just to introduce a product but to revolutionize the standard of care for those suffering from chronic pain after amputation.

Dr. Fouad Azzam from the EQT Life Sciences advisory team reinforced the company's vision, stating that the Altius® system addresses urgent challenges in chronic pain management and could dramatically enhance the lives of amputees. Their partnership with Neuros Medical underscores a shared commitment to innovation in healthcare, aiming to bring effective therapies to market as swiftly as possible.

In conclusion, Neuros Medical is not just raising funds; they are raising hopes. As they prepare to launch Altius®, the company stands ready to offer a life-changing solution to countless individuals grappling with chronic pain after amputation. The journey from funding to commercialization is critical, and the impact of this technology promises to resonate for years to come, potentially transforming the landscape of pain management for amputees.